OverviewSuggest Edit
Zoetis is a company engaged in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products. It offers vaccines, anti-infectives, parasiticides, other pharmaceutical products, dermatology, medicated feed additives, and animal health diagnostics for cattle, swine, poultry, fish, and sheep as well as dogs, cats, and horses.
| Type | Public | |
| Founded | 2012 | |
| HQ | Parsippany-Troy Hills, NJ, US | Map |
| Website | zoetis.com | |
| Employee Ratings | More |
Recent NewsAll News
- After A 10% Rise In A Month Zoetis Stock May Continue To See Higher Levels
- Global Veterinary Diagnostic Equipment Market Report 2021-2025 & 2030: Major Players Include IDEXX Laboratories, ABAXIS, HESKA Corporation, Zoetis and Virbac
- Does The Valuation Gap Between Merck Stock And Zoetis Make Sense?
- Global Animal Health Market (2021 to 2025) - Featuring Bayer, Eli Lilly and Zoetis Among Others
Key People/Management at Zoetis
Kristin Peck
Chief Executive Officer and Director
Tim Bettington
Executive Vice President and President, U.S. Operations
Glenn David
Executive Vice President and Chief Financial Officer
Heidi Chen
Executive Vice President, General Counsel and Corporate Secretary
Rob Kelly
Executive Vice President and President, International Operations
Wetteny Joseph
Executive Vice President and Chief Financial Officer
Zoetis Office Locations
Zoetis has offices in Parsippany-Troy Hills, DXS, Silverwater, Wien and in 45 other locations
Parsippany-Troy Hills, NJ, US (HQ)
10 Sylvan Way, Parsippany
DXS, AR
Virrey Loreto 2477
Wien, AT
Floridsdorfer Hauptstraße 1
Zaventem, BE
Mercuriusstraat 20
Sao Paulo, BR
Rua Luiz Fernando Rodrigues 1701
Kirkland, CA
16740 Route Transcanadienne
Zoetis Financials and Metrics
Zoetis Revenue
Zoetis's revenue was reported to be $6.68 b in FY, 2020
| USD | |
|---|---|
Revenue (Q1, 2021) | 1.9b |
Gross profit (Q1, 2021) | 1.3b |
Gross profit margin (Q1, 2021), % | 70.7% |
Net income (Q1, 2021) | 558.0m |
Market capitalization (22-Jul-2021) | 95.2b |
Closing stock price (22-Jul-2021) | 200.5 |
Cash (31-Mar-2021) | 3.6b |
EV | 99.0b |
Zoetis's current market capitalization is $95.2 b.
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.4b | 1.4b | 1.5b | 1.5b | 1.5b | 1.6b | 1.5b | 1.5b | 1.8b | 1.9b |
Cost of goods sold | 447.0m | 447.0m | 473.0m | 518.0m | 465.0m | 479.0m | 459.0m | 451.0m | 546.0m | 549.0m |
Gross profit | 919.0m | 968.0m | 1.0b | 937.0m | 1.1b | 1.1b | 1.1b | 1.1b | 1.2b | 1.3b |
Gross profit Margin, % | 67% | 68% | 68% | 64% | 70% | 70% | 70% | 71% | 69% | 71% |
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash | 1.7b | 1.6b | 1.3b | 1.7b | 1.8b | 1.8b | 2.0b | 3.4b | 3.7b | 3.6b |
Accounts Receivable | 943.0m | 973.0m | 929.0m | 970.0m | 994.0m | 1.0b | 965.0m | 984.0m | 1.0b | 1.1b |
Inventories | 1.4b | 1.4b | 1.4b | 1.4b | 1.4b | 1.4b | 1.5b | 1.6b | 1.6b | 1.7b |
Current Assets | 4.3b | 4.2b | 4.1b | 4.4b | 4.5b | 4.6b | 4.8b | 6.3b | 6.8b | 6.8b |
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 350.0m | 732.0m | 1.1b | 312.0m | 683.0m | 1.1b | 423.0m | 799.0m | 1.3b | 558.0m |
Depreciation and Amortization | 60.0m | 123.0m | 207.0m | 98.0m | 196.0m | 303.0m | 110.0m | 221.0m | 332.0m | 109.0m |
Inventories | (33.0m) | (23.0m) | 29.0m | 17.0m | (50.0m) | (103.0m) | (97.0m) | (233.0m) | (294.0m) | (84.0m) |
Accounts Payable | (46.0m) | (28.0m) | (39.0m) | (79.0m) | (22.0m) | (28.0m) | (35.0m) | 37.0m | 49.0m | (112.0m) |
| USD | FY, 2017 |
|---|---|
Revenue/Employee | 576.8k |
Debt/Equity | 2.8 x |
Debt/Assets | 0.6 x |
Financial Leverage | 4.8 x |
Zoetis Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Performance Livestock Analytics | April 08, 2020 | |
| Ethos Diagnostic Science | February 07, 2020 | |
| Platinum Performance | July 22, 2019 | |
| Abaxis | May 15, 2018 | $1.9 b |
| Nexvet | April 03, 2017 | $85 m |
| Scandinavian Micro Biodevices | August 08, 2016 | $80 m |
| PHARMAQ | November 02, 2015 | $765 m |
| Bovigen | March 18, 2008 | |
| Abaxis Asia Holding Limited | ||
| Abaxis Europe GmbH |
Zoetis Revenue Breakdown
Zoetis revenue breakdown by business segment: 7.6% from Medicated Feed Additives, 12.4% from Dermatology, 12.6% from Other Pharmaceuticals, 15.6% from Parasiticides, 20.2% from Anti-infectives, 23.9% from Vaccines and 7.6% from Other
Zoetis revenue breakdown by geographic segment: 6.0% from Other Developed Markets, 12.0% from Other Emerging Markets, 51.9% from United States and 30.2% from Other
Zoetis Cybersecurity Score
Zoetis Environment, Social & Governance (ESG) Ratings
Zoetis Online and Social Media Presence
14.04k Twitter followers
Zoetis has 14.04k Twitter Followers. The number of followers has increased 1% month over month and increased 1.2% quarter over quarter
Zoetis's Trends
Twitter Engagement Stats for @Zoetis
2k
Tweets
364
Following
14k
Followers
9
Tweets last 30 days
24
Avg. likes per Tweet
77.8%
Tweets with engagement
Zoetis News and Updates
July 08, 2021
After A 10% Rise In A Month Zoetis Stock May Continue To See Higher Levels
The stock price of Zoetis, an animal health company, has seen a 10% rise over the last twenty-one trading days, while it is up 40% over the last year. ZTS stock has benefited from an increased animal adoption in the U.S., which aided its sales for parasiticide products for companion animals...
June 29, 2021
Global Veterinary Diagnostic Equipment Market Report 2021-2025 & 2030: Major Players Include IDEXX Laboratories, ABAXIS, HESKA Corporation, Zoetis and Virbac
Dublin, June 29, 2021 (GLOBE NEWSWIRE) -- The "Veterinary Diagnostic Equipment Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering. The global veterinary diagnostic equipment market is expected to grow from $0.74 billion in 20…
June 21, 2021
Does The Valuation Gap Between Merck Stock And Zoetis Make Sense?
Zoetis stock has risen 2x from levels of $92 that it was at on March 23, 2020, when broader markets made a bottom, to levels of $184 now, while Merck’s stock has underperformed and gained only 26% of its value. Looking at valuation, Merck stock trades at about 4x trailing revenues, compared...
May 25, 2021
Global Animal Health Market (2021 to 2025) - Featuring Bayer, Eli Lilly and Zoetis Among Others
Dublin, May 25, 2021 (GLOBE NEWSWIRE) -- The "Global Animal Health Market (Feed Additives, Pharmaceuticals & Vaccines): Insights & Forecast with Potential Impact of COVID-19 (2021-2025)" report has been added to ResearchAndMarkets.com's offering.
November 26, 2020
Europe Companion Animal Diagnostics Market Set to Expand by 2020-2027 Focusing on Key Players Zoetis Inc, Randox Laboratories, Ltd., Idexx Laboratories, Inc., IDvet, Virbac
The Europe companion animal diagnostics market is to reach US$ 792.8 million by 2027 from US$ 613.6 million in 2019. The market is anticipated to grow at a CAGR of 3.8% during 2019–2027. Posted via Industry Today. Follow us on Twitter @IndustryToday
November 11, 2020
Companion Animal Diagnostics Market examined in new market research report by top companies Skyla, Randox Laboratories, IDEXX Laboratories, Zoetis
The companion animal diagnostics marketwas valued at US$ 2,031.62 million in2019 and is projected to reach US$ 2,684.86 million by 2027; it is expected to grow at a CAGR of 4.1%from 2020to 2027. Posted via Industry Today. Follow us on Twitter @IndustryToday
Zoetis Frequently Asked Questions
When was Zoetis founded?
Zoetis was founded in 2012.
Who are Zoetis key executives?
Zoetis's key executives are Kristin Peck, Tim Bettington and Glenn David.
How many employees does Zoetis have?
Zoetis has 10,600 employees.
What is Zoetis revenue?
Latest Zoetis annual revenue is $6.7 b.
What is Zoetis revenue per employee?
Latest Zoetis revenue per employee is $629.7 k.
Who are Zoetis competitors?
Competitors of Zoetis include VCA, Elanco and IDEXX Laboratories.
Where is Zoetis headquarters?
Zoetis headquarters is located at 10 Sylvan Way, Parsippany, Parsippany-Troy Hills.
Where are Zoetis offices?
Zoetis has offices in Parsippany-Troy Hills, DXS, Silverwater, Wien and in 45 other locations.
How many offices does Zoetis have?
Zoetis has 50 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies